サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1408631

欧州のゲノムがんパネルとプロファイリング市場：分析と予測（2023年～2033年）

Europe Genomic Cancer Panel and Profiling Market: Analysis and Forecast, 2023-2033
出版日: | 発行: BIS Research | ページ情報: 英文 92 Pages | 納期: 1～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
欧州のゲノムがんパネルとプロファイリング市場：分析と予測（2023年～2033年）
出版日: 2024年01月16日
発行: BIS Research
ページ情報: 英文 92 Pages
納期: 1～5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

2023年現在、欧州のゲノムがんパネルとプロファイリングの市場規模は26億4,000万米ドルとなっており、2033年には65億米ドルに達すると予測されています。

予測期間の2023年～2033年のCAGRは9.42%になると見込まれています。この成長の原動力となっているのは、ゲノム研究の進展と腫瘍学における精密治療の重視の高まりです。

主要市場統計
予測期間 2023年～2033年
2023年評価 26億4,000万米ドル
2033年予測 65億米ドル
CAGR 9.42%

ゲノムがんパネルとプロファイリングは、症状が現れる前に悪性腫瘍の遺伝的特徴を調べる、がん検出のための現代的な手法です。これらのパネルが広範な遺伝学的洞察を提供できるため、早期発見が容易になり、オーダーメイドの治療戦略の開発が容易になるという大きな利点があります。ゲノムがんパネルおよびプロファイリング市場が拡大しているのは、これらの技術ががん管理を変える変革の可能性を秘めているからです。これらのパネルは、ヘルスケア提供者が特定の遺伝的変化を特定し、それに応じて介入をカスタマイズできるようにすることで、がん遺伝学に対する理解を向上させます。

欧州市場では、遺伝子がんパネルとプロファイリングががんのスクリーニングと管理のために人気を集めています。これらの最新技術は、悪性腫瘍に関する詳細な遺伝子情報を提供し、早期発見と個別の治療レジメンを可能にします。これらのパネルは、がん管理を一変させる可能性があるため、需要が増加しています。欧州における市場拡大の要因としては、リキッドバイオプシー検査の普及、ライフスタイルの変化によるがんリスクの増加、早期発見の必要性などが挙げられます。

当レポートでは、欧州のゲノムがんパネルとプロファイリング市場について調査し、市場の概要とともに、用途別、エンドユーザー別、国別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

第1章 市場

  • 市場範囲
  • 調査手法
  • 市場概要

第2章 業界分析

  • 法的要件
  • 特許分析

第3章 市場力学

  • 概要
    • 影響分析
  • 市場促進要因
  • 市場抑制要因
  • 市場機会

第4章 競合考察

  • 概要
  • 主要な戦略と展開
  • 成長シェア分析

第5章 地域別

  • 概要
  • 欧州
    • 主要なダイナミクス
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他の地域

第6章 企業プロファイル

  • F. Hoffmann-La Roche Ltd
図表

List of Figures

  • Figure 1: Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
  • Figure 2: Genomic Cancer Panel and Profiling Market (by Application), % Share, 2022 and 2033
  • Figure 3: Genomic Cancer Panel and Profiling Market (by End User), % Share 2022 and 2033
  • Figure 4: Genomic Cancer Panel and Profiling Market Snapshot (by Region), $Billion, 2022
  • Figure 5: Genomic Cancer Panel and Profiling Market: Research Methodology
  • Figure 6: Primary Research Methodology
  • Figure 7: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 8: Top-Down Approach (Segment-Wise Analysis)
  • Figure 9: Genomic Cancer Panel and Profiling Workflow, End User Perspective
  • Figure 10: Genomic Cancer Panel and Profiling Workflow, Laboratory Technician Perspective
  • Figure 11: Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
  • Figure 12: General Testing Criterion According to the NCCN Guidelines
  • Figure 13: Reimbursement Components in the U.S.
  • Figure 14: Genomic Cancer Panel and Profiling Market, Patent Analysis (by Year), January 2020-October 2023
  • Figure 15: Genomic Cancer Panel and Profiling Market, Patent Analysis (by Country), January 2020-October 2023
  • Figure 16: Genomic Cancer Panel and Profiling Market Dynamics
  • Figure 17: Cancer Profiling Cases in Developed Countries
  • Figure 18: Share of Global Cancer Prevalence, 2010-2019
  • Figure 19: Share of Global Age-Standardized Death Rate of Cancer, 2010-2019
  • Figure 20: Genomic Research Funding by National Human Genome Research Institute (NHGRI), $Million, 2020, 2021, and 2022
  • Figure 21: Key Players Offering
  • Figure 22: Reimbursement Reductions Adopted for Oncology Testing as per PAMA Revisions
  • Figure 23: Cost Difference between the Multi-Gene Panel Test and Usual Care Screening Test
  • Figure 24: Share of Key Developments, January 2020-October 2023
  • Figure 25: Number of Product Launches, Approvals, and Upgradations (by Company), January 2020-October 2023
  • Figure 26: Growth-Share Analysis of the Genomic Cancer Panel and Profiling Market (by Technology), 2022
  • Figure 27: Genomic Cancer Panel and Profiling Market Snapshot (by Region), $Billion, 2022
  • Figure 28: Europe Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
  • Figure 29: Europe Genomic Cancer Panel and Profiling Market (by Application), $Million, 2022-2033
  • Figure 30: Europe Genomic Cancer Panel and Profiling Market (by End User), $Million, 2022-2033
  • Figure 31: Europe Genomic Cancer Panel and Profiling Market (by Country), $Billion, 2022-2033
  • Figure 32: Germany Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
  • Figure 33: France Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
  • Figure 34: U.K. Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
  • Figure 35: Italy Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
  • Figure 36: Spain Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
  • Figure 37: Rest-of-Europe Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
  • Figure 38: Genomic Cancer Panel and Profiling Market, Total Number of Companies Profiled
  • Figure 39: F. Hoffmann-La Roche Ltd: Product Portfolio
  • Figure 40: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2020-2022
  • Figure 41: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2020-2022
  • Figure 42: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2020-2022

List of Tables

  • Table 1: Genomic Cancer Panel and Profiling Market, Impact Analysis
  • Table 2: Technological Trends in the Genomic Cancer Panel and Profiling Market
  • Table 3: Genomic Cancer Panel and Profiling Market, Impact Analysis
  • Table 4: Genomic Cancer Panel and Profiling Market, Pipeline Tests
  • Table 5: Ongoing Cancer-Based Biomarkers Trials
  • Table 6: Europe Genomic Cancer Panel and Profiling Market, Impact Analysis
目次
Product Code: BHP1775SS

“The Europe Genomic Cancer Panel and Profiling Market Expected to Reach $6.50 Billion by 2033.”

Introduction to Europe Genomic Cancer Panel and Profiling Market

As of 2023, the Europe genomic cancer panel and profiling market was valued at $2.64 billion and is expected to attain a value of $6.50 billion in 2033. The market is anticipated to grow at a CAGR of 9.42% during the forecast period 2023-2033. This growth is being driven by advances in genomic research and an increasing emphasis on precision therapy in oncology.

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$2.64 Billion
2033 Forecast$6.50 Billion
CAGR9.42%

Market Introduction

Genomic cancer panels and profiling are a contemporary technique to cancer detection that examines the genetic characteristics of malignancies before symptoms occur. The capacity of these panels to provide extensive genetic insights facilitates early detection and the development of tailored treatment strategies, which is a considerable advantage. The genomic cancer panel and profiling market is expanding because to the transformational potential these technologies have for changing cancer management. These panels improve our understanding of cancer genetics by allowing healthcare providers to identify particular genetic changes and customize interventions accordingly.

In the European market, genetic cancer panels and profiling are gaining popularity for cancer screening and management. These modern technologies provide detailed genetic information about malignancies, allowing for early detection and individualized treatment regimens. The demand for these panels is increasing as a result of their transformational potential in changing cancer management. Factors driving market expansion in Europe include the growing popularity of liquid biopsy testing, increased cancer risk due to lifestyle changes, and the need for early detection.

Market Segmentation

Segmentation 1: by Application

  • Clinical
  • Research

Segmentation 2: by End User

  • Hospitals
  • Clinical and Diagnostic Laboratories
  • Research and Academic Institutes
  • Other End Users

Segmentation 3: by Country

  • U.K.
  • France
  • Italy
  • Germany
  • Spain

How can this report add value to an organization?

Product/Innovation Strategy: The Europe genomic cancer panel and profiling market has been extensively segmented based on various categories, such as application, end user, and country. This can help readers get a clear overview of the segments accounting for the largest share and the ones that are well-positioned to grow in the coming years.

Table of Contents

Executive Summary

1. Markets

  • 1.1. Market Scope
    • 1.1.1. Key Questions Answered in this Report
  • 1.2. Research Methodology
    • 1.2.1. Genomic Cancer Panel and Profiling Market: Research Methodology
    • 1.2.2. Data Sources
    • 1.2.3. Market Estimation Model
    • 1.2.4. Criteria for Company Profiling
  • 1.3. Market Overview
    • 1.3.1. Market Definition
    • 1.3.2. Market Footprint and Growth Potential
    • 1.3.3. Future Potential

2. Industry Analysis

  • 2.1. Legal Requirements
    • 2.1.1. Regulation of Genetic Tests
    • 2.1.2. NCCN Guidelines
    • 2.1.3. Reimbursement Scenario
  • 2.2. Patent Analysis
    • 2.2.1. Patent Filing Trend
    • 2.2.2. Patent Analysis (by Year)
    • 2.2.3. Patent Analysis (by Country)

3. Market Dynamics

  • 3.1. Overview
    • 3.1.1. Impact Analysis
  • 3.2. Market Drivers
    • 3.2.1. Rising Need for Cancer Profiling in Developed Countries Driving Demand for Genomic Panels and Profiling Tests
    • 3.2.2. Increase in Genomic Research Funding Expanding the Market for Genomic Cancer Panels and Profiling
    • 3.2.3. Technological Advancements in the Field of Informatics Expanding Consumer Reach
  • 3.3. Market Restraints
    • 3.3.1. Significant Implications of Reimbursement Reductions Impacting Growth of the Genomic Cancer Panel and Profiling Market
    • 3.3.2. Impact of High-Cost Pressure Hindering Development in Genomic Cancer Panel and Profiling Testing
  • 3.4. Market Opportunities
    • 3.4.1. Robust Pipeline of Genomic Cancer Panels and Profiling Tests Poised to Revolutionize Cancer Diagnosis
    • 3.4.2. Discovery of New Biomarkers Presents an Opportunity for the Development of Diagnostics Tools and Technologies

4. Competitive Insights

  • 4.1. Overview
  • 4.2. Key Strategies and Developments
    • 4.2.1. Product Launches, Approvals, and Upgradations
    • 4.2.2. Synergistic Activities
    • 4.2.3. Mergers and Acquisitions
    • 4.2.4. Business Expansions, Funding, and Licenses
  • 4.3. Growth-Share Analysis
    • 4.3.1. Growth-Share Analysis (by Technology), 2022

5. By Region

  • 5.1. Overview
  • 5.2. Europe
    • 5.2.1. Key Dynamics
    • 5.2.2. Germany
    • 5.2.3. France
    • 5.2.4. U.K.
    • 5.2.5. Italy
    • 5.2.6. Spain
    • 5.2.7. Rest-of-Europe

6. Company Profiles

  • 6.1. Overview
  • 6.2. F. Hoffmann-La Roche Ltd
    • 6.2.1. Company Overview
    • 6.2.2. Role of F. Hoffmann-La Roche Ltd in the Genomic Cancer Panel and Profiling Market
    • 6.2.3. Corporate Strategies
    • 6.2.4. Business Strategies
    • 6.2.5. Financials
    • 6.2.6. Analyst Perspective